Shares of Cryolife Inc (NYSE:CRY) have earned an average recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $24.83.
Several brokerages recently weighed in on CRY. Northland Securities reissued a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a report on Monday, November 13th. TheStreet lowered Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Zacks Investment Research raised Cryolife from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a report on Wednesday, January 3rd.
Shares of Cryolife (NYSE:CRY) traded up $0.35 during trading on Tuesday, reaching $18.25. The company had a trading volume of 87,302 shares, compared to its average volume of 85,740. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.90 and a current ratio of 5.96. The company has a market capitalization of $659.56, a price-to-earnings ratio of 65.18 and a beta of 0.77. Cryolife has a 1 year low of $14.02 and a 1 year high of $24.00.
A number of institutional investors have recently made changes to their positions in CRY. Teacher Retirement System of Texas bought a new stake in Cryolife in the fourth quarter valued at about $197,000. Cornerstone Capital Management Holdings LLC. grew its holdings in shares of Cryolife by 161.5% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 10,200 shares of the medical equipment provider’s stock valued at $203,000 after purchasing an additional 6,300 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new position in shares of Cryolife during the fourth quarter valued at approximately $203,000. Crossmark Global Holdings Inc. bought a new position in shares of Cryolife during the third quarter valued at approximately $259,000. Finally, Stifel Financial Corp bought a new position in shares of Cryolife during the third quarter valued at approximately $275,000. 72.60% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Cryolife Inc (CRY) Given Average Recommendation of “Hold” by Analysts” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.thelincolnianonline.com/2018/02/18/cryolife-inc-cry-given-average-recommendation-of-hold-by-analysts.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.